FLASCO

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal and Kidney Cancer

  • FLASCO
  • September 29, 2016

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal. These NCCN Guidelines® are currently available as Version 2.2016. 

  • The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

*For your reference, the previous update (Version 1.2016) to the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, published on July 11, 2016, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf
NCCN has published updates to the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Kidney Cancer. These NCCN Guidelines are currently available as Version 1.2017. 

  • Initial workup (KID-1)
    • Abdominal/pelvic CT was changed to “Abdominal ± pelvic CT.”
    • Chest imaging was clarified as “chest x-ray” and “chest CT” is listed as “If clinically indicated”.
  • Primary treatment
    • For Stage I (pT1a), the option for ablative techniques was revised as, “Ablative techniques in selected patients .”  (KID-1)
    • For Stage II, III, the option for “partial nephrectomy, if clinically indicated” was added. (KID-1)
  • First-line therapy for relapsed or stage IV and surgically unresectable with predominant clear cell histology (KID-3)
    • The first-line therapy options were reorganized and “alphabetical by category and preference” was added to the heading.
    • Sunitinib (category 1) and pazopanib (category 1) are listed as “preferred” options.
  • Subsequent therapy for relapsed or stage IV and surgically unresectable with predominant clear cell histology (KID-3)
    • The subsequent therapy options were reorganized by removing the “after antiangiogenic therapy” and “after cytokine therapy” categories and listing “alphabetical by category and preference” to the heading.
    • Cabozantinib (category 1) and nivolumab (category 1) are listed as “preferred” options.
    • The NCCN category of evidence and consensus was revised as follows:
      • Lenvatinib + everolimus regimen was changed from a category 2A to category 1.
      • Everolimus was category 1 after antiangiogenic therapy and after cytokine therapy and is now a category 2A.
      • Pazopanib was category 2A after antiangiogenic therapy and a category 1 after cytokine therapy and is now a category 2A.
      • Sorafenib was category 2A after antiangiogenic therapy and a category 1 after cytokine therapy and is now a category 2A.
      • Sunitinib was category 2A after antiangiogenic therapy and a category 1 after cytokine therapy and is now a category 2A.
    • Systemic therapy for relapsed or stage IV and surgically unresectable with non-clear cell histology (KID-4)
      • The systemic therapy options were reorganized and “alphabetical by category and preference” was added to the heading.
      • Sunitinib is noted as the “preferred” option.
      • The following systemic therapy options were added:
        • Cabozantinib (category 2A)
        • Lenvatinib + everolimus (category 2A)
        • Nivolumab (category 2A)
      • Follow-up (KID-B)
        • Pelvic imaging was clarified as, “Pelvic CT or MRI, as clinically indicated”

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To access the NCCN Biomarkers Compendium®, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.

Who’s Online

There are no users currently online